Bharat Biotech International Ltd., an Indian vaccine maker, will ramp up production of its Covid-19 shot to about 700 million doses on an annual basis as the country struggles to contain a fresh and virulent coronavirus wave.
The planned expansion comes after India’s government last week gave the firm a Rs 65-crore ($8.7 million) grant. New Delhi has pushed Bharat Biotech to double its output by June and churn out nearly 100 million doses of its inactivated Covaxin shot per month by September as the nation reports record daily infection and death rates.
“Inactivated vaccines, while highly safe, are extremely complex and expensive to manufacture, resulting in lower yields when compared to live virus vaccines,” the Hyderabad-based company said in a statement on Tuesday. “Manufacturing partnerships are being explored with our partners in other countries, who have prior expertise with commercial scale manufacture of inactivated viral vaccines under biosafety containment.”
Capacity expansion has been implemented across multiple facilities in Hyderabad and Bengaluru, to reach 700 million doses per year, one of the largest production capacities for inactivated viral vaccines worldwide, said the firm.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.